Nearly 50 Cell and Gene Therapies Benefit From New FDA Flexibility

Cell and gene therapies are a new class of medicines that use living cells or genetic material to treat serious diseases, often targeting rare genetic disorders, blood cancers, and certain immune system conditions. Most of these therapies have only been developed and approved in the last ten years, making them a rapidly evolving part of medicine. As interest grows, the U.S. Food and Drug Administration is updating how it reviews these products. The agency’s new, more flexible approach reflects the latest scientific advances while keeping patient safety at the forefront. By providing clearer guidelines and allowing developers to adjust manufacturing and testing as therapies progress, the FDA aims to reduce unnecessary delays and make it easier for innovators to bring new treatments to patients.

Then Vs. Now: Why FDA Rules Had to Change

Unlike traditional drugs made through fixed chemical processes, cell and gene therapies rely on living cells or engineered genetic material. These products can change as they are manufactured, refined, or scaled, especially in early development. As a result, progress is often less predictable.

Older regulatory models were designed for stable products with finalized manufacturing methods early on. For advanced therapies, those expectations sometimes slowed clinical trials or forced redesigns before developers fully understood how their products behaved. The FDA acknowledged this mismatch and concluded that review standards needed to better reflect how these therapies evolve over time.

What Flexibility Looks Like in Practice

The FDA’s updated approach affects how cell and gene therapies move through clinical testing, manufacturing, and eventual approval. During early and mid stage trials, manufacturers are no longer expected to meet the same production standards required for fully approved drugs (21 CFR part 211). Instead, regulators review manufacturing and testing using a lifecycle approach, recognizing that methods and controls improve as developers gain experience. In practice, this means smaller biotech companies can start clinical trials sooner without being held back by rules designed for large pharmaceutical factories, helping patients access promising therapies faster.

Product quality standards can also remain provisional during investigational studies. Final specifications for the therapy are not required until later in development, allowing early trials to proceed with acceptance criteria that are appropriate for research use rather than commercial supply (21 CFR 312.23(a)(7)). As products advance into studies designed to demonstrate effectiveness, the FDA will also allow limited manufacturing changes, provided data show that the therapy remains comparable before and after the change. This flexibility allows developers to refine and improve therapies while they are still being tested in patients, instead of delaying trials to meet rigid production benchmarks. 

For therapies moving toward approval, the agency is also adjusting expectations around commercial specifications. Because many cell and gene therapies serve very small patient populations, manufacturers may not be able to produce large numbers of batches. The FDA said it will consider more flexible product release standards when reviewing applications, as long as quality and consistency are supported by evidence. After approval, companies may also request updates to release criteria based on real world manufacturing experience, if they can demonstrate stable product performance. For patients, this could mean faster access to therapies for rare diseases, since companies do not have to wait to make large amounts of product before receiving approval. It also gives developers room to learn and optimize production once the therapy is in use.

The FDA is also rethinking how process validation is handled. There is no fixed requirement to produce three validation batches, a long standing benchmark for traditional drugs. In some cases, validation batches may even be released to patients before all protocol steps are completed, a practice known as concurrent release. Reviewers instead evaluate whether the number of batches used makes sense based on overall understanding of the manufacturing process. This approach lets companies get therapies to patients sooner while regulators ensure that the manufacturing process is well understood and reliable, balancing speed with safety.

Clearer Guidance Without Weaker Oversight

Many of these practices were already used during individual reviews, but they were not always clearly communicated. By formally outlining them, the FDA aims to improve consistency and predictability across the field. This transparency helps both established companies and newer research groups plan development more effectively.

FDA officials emphasized that flexibility does not reduce oversight. Safety and quality remain central to regulatory decisions, and ongoing communication between regulators and developers is encouraged. Through this approach, the agency seeks to support innovation while maintaining public confidence in approved therapies.

Author

[email protected]